Morningstar

Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation

Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced enrollment of the first patients in its ...

Create simple UX for domain-specific languages with VS Code

Generic formats like JSON or XML are easier to version than forms. However, they were not originally intended to be human-readable but machine-readable. Since many applications require a ...
Finanznachrichten

Pulse Biosciences, Inc.: Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse Cardiac Catheter System for Atrial Fibrillation

U.S. IDE Enrollment follows groundbreaking 96% procedural success at 12 months in European feasibility study Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse technology using proprietary ...